Andrei Afanasiev

Andrei Afanasiev is a distinguished CEO and Head of Research and Development, leveraging over 15 years of experience in the pharma and biotech industry. With a solid background in R&D, business development, and venture capital projects, Andrei's expertise spans from the preclinical stage to stage III clinical trials in drug development.

Having founded and led 3 successful startups in bioinformatics SaaS, genetic testing, and cancer treatment, one of which achieved a lucrative exit through M&A with a strategic investor, Andrei has a proven track record of entrepreneurial success.

As a former R&D Director at a pharmaceutical company overseeing a substantial annual budget of $15M, Andrei is skilled in research strategy development, preclinical study management, and project oversight within the pharmaceutical sector. He excels in fostering collaboration across cross-functional teams and stakeholders, including production, medical, marketing, and regulatory departments.

Andrei's scientific proficiency extends to machine learning and genetics, evidenced by over 100 public talks, 7 authored papers, and 2 secured patents. Beyond his professional endeavors, Andrei is passionate about science popularization, community building, and actively mentors startups and students.

Andrei Afanasiev pursued his education in Specialist Nuclear Physics at Lomonosov Moscow State University (MSU) and has extensive experience with prominent organizations in various roles, including Venture Partner at Sky High VC, Advisor at Focal Reasonance, and Scientific Consultant at Unison, among others.